EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SARS‐CoV‐2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan‐coronavirus fusion inhibitors

Shuai Xia, Fanke Jiao, Lijue Wang, Xueying Yu, Tianyu Lu, Yan Fu, Ziqi Huang, Xicheng Li, Jinghe Huang, Qian Wang, Qiuhong Man, Lize Xiong und 2 weitere

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28641 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Shuai Xia und 13 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Scienc…. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Numerous emerging severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron subvariants have shown significant immune evasion capacity and caused a large number of infections, as well as vaccine‐breakthrough infections, especially in elderly populations. Recently emerged Omicron XBB was derived from the BA.2 lineage, but bears a distinct mutant profile in its spike (S) protein. In this study, we found that Omicron XBB S protein drove more efficient membrane‐fusion kinetics on human lung‐derived cells (Calu‐3). Considering the high susceptibility of the elderly to the current Omicron pandemic, we performed a comprehensive neutralization assessment of elderly convalescent or vaccine sera against XBB infection. We found that the sera from elderly convalescent patients who experienced with BA.2 infection or breakthrough infection potently inhibited BA.2 infection, but showed significantly reduced efficacy against XBB. Moreover, recently emerged XBB.1.5 subvariant also showed more significant resistance to the convalescent sera of BA.2‐ or BA.5‐infected elderly. On the other hand, we found that the pan‐CoV fusion inhibitors EK1 and EK1C4 can potently block either XBB‐S‐ or XBB.1.5‐S‐mediated fusion process and viral entry. Moreover, EK1 fusion inhibitor showed potent synergism when combined with convalescent sera of BA.2‐ or BA.5‐infected patients against XBB and XBB.1.5 infection, further indicating that EK1‐based pan‐CoV fusion inhibitors are promising candidates for development as clinical antiviral agents to combat the Omicron XBB subvariants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19AgedHumansImmune EvasionCOVID-19 SerotherapyAnti-Retroviral AgentsBreakthrough InfectionsSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, Viral

Stichwörter der Autor:innen

Omicron XBB subvariantSARS-CoV-2elderly convalescentfusion inhibitorfusogenicity

Substanzen

Anti-Retroviral AgentsSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, Viralspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infec…
  • Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital, School of Medicine, Tongji University,…
  • Department of Anesthesiology and Perioperative Medicine, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.

ORCID-Profile: Shibo Jiang

Zitieren

APA

Xia, S., Jiao, F., Wang, L., Yu, X., Lu, T., Fu, Y., Huang, Z., Li, X., Huang, J., Wang, Q., Man, Q., Xiong, L., Jiang, S., & Lu, L. (2023). SARS‐CoV‐2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan‐coronavirus fusion inhibitors. Journal of Medical Virology. https://doi.org/10.1002/jmv.28641

Vancouver

Xia S, Jiao F, Wang L, Yu X, Lu T, Fu Y, et al. SARS‐CoV‐2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan‐coronavirus fusion inhibitors. Journal of Medical Virology. 2023. doi:10.1002/jmv.28641

BibTeX
@article{Xia2023,
  author = {Xia, Shuai and Jiao, Fanke and Wang, Lijue and Yu, Xueying and Lu, Tianyu and Fu, Yan and Huang, Ziqi and Li, Xicheng and Huang, Jinghe and Wang, Qian and Man, Qiuhong and Xiong, Lize and Jiang, Shibo and Lu, Lu},
  title = {SARS‐CoV‐2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan‐coronavirus fusion inhibitors},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28641}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche